
|Videos|March 18, 2022
- MHE March 2022
- Volume 32
- Issue 3
William Dietz of George Washington University Talks About the Importance of Obesity on COVID-19
Author(s)Briana Contreras
William Dietz, MD, PhD, Professor and Director of Sumner M. Redstone Global Center for Prevention and Wellness at George Washington University, addressed to MHE the degree obesity is a risk factor at for severe COVID-19 and what those reasons are for obesity increasing the risk. This video is in correlation to Managed Healthcare Executive's March Issue cover story highlighting the dangerous pairing of COVID-19 and Obesity.
Advertisement
Articles in this issue
over 4 years ago
The Cost Burden of Alzheimer'sover 4 years ago
Frequent and Feared. But Can Dementia Be Avoided?over 4 years ago
Cancer Mortality is Decreasing in the U.S.over 4 years ago
New TEFCA Framework Brings Some Clarity to Interoperability Pushover 4 years ago
Fourth Shot is Recommended for the Immunocompromisedover 4 years ago
New COVID-19 Vaccines are in Late-stage Trialsover 4 years ago
Insurers and COVID-19 TestsAdvertisement
Related to this article

Nelkarmi gives ALK-positive lung cancer patients a new option after first-line therapy stops working
The FDA granted accelerated approval to GSK's Nelkarmi for previously treated ALK-positive NSCLC, the company's second lung cancer approval this year.

A pooled review of 40 studies tied type 2 diabetes to a 53% higher Alzheimer’s risk, with incidence more than doubling when clinicians made the diagnosis.

Lockton's Sarah Klein says employers are already asking hard questions about PBM transparency, even though many of the new rules have not taken effect.

WIC participation is estimated at only 44% of eligible Medicaid enrollees in 2023, and just 15% of pregnant Medicaid enrollees. Health plans can help close that gap, but only if their referrals are tracked through enrollment.

Heidi Overton ran into opposition from Republican senators concerned about her role in setting White House vaccine policy.

Takeda’s Orzeyful, the first orexin agonist for narcolepsy type 1, is now available in the U.S. at a whole acquisition list price of $16,500 per 60-tablet bottle.

The FDA approved Cosentyx for polymyalgia rheumatica after 40.5% of trial patients reached sustained remission at week 52 vs. 20.5% on placebo.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
White House pulls Overton FDA nomination, Marshall might be nominated instead
2
Takeda launches Orzeyful, first orexin agonist for narcolepsy type 1
3
From Keytruda biosimilar to novel ADC: Samsung Bioepis’ 2-track oncology strategy
4
Running social services like a business starts with the referral
5

